RNA Q3 2020 Earnings — Avidity Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RNAAvidity Biosciences, Inc.

$2B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+168.6% YoY

Gross Profit

-$8M-441.5% margin

Operating Income

-$11M-656.7% margin

Net Income

-$11M-655.2% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

+13.3%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$10M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$346M

Total Liabilities

$26M

Stockholders' Equity

$320M

Cash & Equivalents

$341M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$650,000	+168.6%
Gross Profit	-$8M	-$4M	-73.3%
Operating Income	-$11M	-$5M	-120.2%
Net Income	-$11M	-$7M	-71.6%